In his article to the Cambridge Globalist, Rory Garbutt from our chapter in Cambridge in the UK  asks how we can ensure that COVID-19 research, much of which is supported by public funding, can avoid the pitfalls of many other pharmaceuticals and be made widely available for all who need it.